Finance

Beta
Lists
CORT:NASDAQ
Corcept Therapeutics Inc
$72.62
-3.03%
(-2.27) 1D
$72.40
-0.30% (-0.22)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CORT...
Open
$74.77
High
$75.09
Low
$72.58
Mkt. cap
7.80B
Avg. vol.
1.17M
Volume
774.69K
P/E ratio
204.75
52-wk high
$91.00
52-wk low
$28.66
EPS
$0.35
Beta
0.50
Shares outstanding
107.35M
No. of employees
730
Open
$74.77
High
$75.09
Low
$72.58
Mkt. cap
7.80B
Avg. vol.
1.17M
Volume
774.69K
P/E ratio
204.75
52-wk high
$91.00
52-wk low
$28.66
EPS
$0.35
Beta
0.50
Shares outstanding
107.35M
No. of employees
730
Analyst outlook
Analyst Ratings
Based on 5 analysts giving stock ratings to CORT in the past 3 months
Strong Buy
Buy
4
Hold
1
Sell
0
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CORT in the last 3 months.
Highest
Current $72.62
$135.00 (+85.90%)
Average
$97.50 (+34.26%)
Lowest
$72.00 (-0.85%)
News stories
From sources across the web
Profile
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
About Corcept Therapeutics Inc
CEO-
Employees730
FoundedMay 13, 1998
HeadquartersMenlo Park, California, United States
SectorPharmaceutical industry
Website-
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
194.43M
207.64M
202.12M
164.90M
Cost of goods sold
3.43M
4.60M
2.54M
2.88M
Cost of revenue
3.43M
4.60M
2.54M
2.88M
Research and development expenses
60.47M
68.85M
64.86M
66.26M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
103.85M
123.98M
130.24M
145.36M
Operating expense
164.32M
192.82M
195.09M
211.62M
Total operating expenses
167.76M
197.42M
197.64M
214.50M
Operating income
26.68M
10.22M
4.49M
-49.60M
Other non operating income
-
-
-
-
EBT including unusual items
31.69M
15.24M
9.91M
-44.72M
EBT excluding unusual items
31.69M
15.24M
9.91M
-44.72M
Income tax expense
-3.46M
-4.42M
-14.38M
-12.95M
Effective tax rate
-10.91%
-29.03%
-145.09%
28.97%
Other operating expenses
-
-
-
-
Net income
35.15M
19.67M
24.29M
-31.76M
Net profit margin
18.08%
9.47%
12.02%
-19.26%
Earnings per share
0.29
0.16
0.20
-0.30
Interest and investment income
5.02M
5.02M
5.42M
4.89M
Interest expense
-
-
-
-
Net interest expenses
5.02M
5.02M
5.42M
4.89M
Depreciation and amortization charges
-
-
-
-
EBITDA
26.96M
10.51M
4.78M
-49.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer